Iradimed Shares Fall on Lower Full-Year Revenue, Earnings Guidance

Dow Jones10-31
 
 

Shares of Iradimed fell after the company lowered its full-year revenue and earnings guidance.

Shares fell 8% to $79.17 on Friday, on pace for its lowest close since October 2025. The stock is down 19% year to date.

The manufacturer of medical devices lowered its full-year revenue outlook to between $91.6 million and $93.1 million, compared with its previous guidance of $91 million to $96 million. Analysts polled by FactSet expect $92.1 million.

The company now expects earnings per share between $1.90 and $1.94, compared with its previous guidance of $1.90 and $2.05. Iradimed now expects adjusted earnings per share between $2.07 and $2.11, compared with its previous guidance between $2.06 and $2.21.

Analysts polled by FactSet expect full-year earnings per share and adjusted earnings per share at $1.94 and $2.11, respectively.

The lowered guidance comes after Iradimed posted a third-quarter profit of $6.5 million, or 51 cents a share, compared with $5.6 million, or 43 cents a share, in the prior year.

On an adjusted basis, per-share earnings were 55 cents. Analysts were looking for 55 cents.

Revenue came in at $24.2 million, up from $21.2 million last year. Analysts expected $23.5 million. The company said the increased revenue was driven by the launch of its new pump.

Iradimed also issued guidance for its current quarter on the lower end of analyst expectations.

For the fourth quarter, the company expects revenue between $25 million and $26.5 million, compared with analyst expectations of $26.2 million.

It also expects earnings per share between 53 cents and 57 cents, and adjusted earnings per share between 57 cents and 61 cents. Analysts were looking for 58 cents and 63 cents, respectively.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment